Mineralys Therapeutics (MLYS) Other Non-Current Assets (2022 - 2026)
Mineralys Therapeutics (MLYS) posted Other Non-Current Assets of $360000.0 for Q1 2026, down 5.76% sequentially from $382000.0 in Q4 2025, and down 9.32% YoY from $397000.0 in Q1 2025.
Mineralys Therapeutics (MLYS) Other Non-Current Assets (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Other Non-Current Assets for 5 years, with the latest figure at $360000.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 9.32% year-over-year to $360000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $360000.0 (down 9.32% YoY) and the FY2025 annual result came in at $382000.0, down 23.45% from the prior year.
- Other Non-Current Assets declined to $360000.0 in Q1 2026 per MLYS's latest filing, from $382000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $1.6 million in Q4 2022 and troughed at $39000.0 in Q1 2023.
- A 5-year average of $379857.1 and a median of $380500.0 in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets sank 96.87% in 2023, then soared 878.43% in 2024.
- Over 5 years, Other Non-Current Assets stood at $1.6 million in 2022, then tumbled by 96.87% to $51000.0 in 2023, then jumped by 878.43% to $499000.0 in 2024, then decreased by 23.45% to $382000.0 in 2025, then fell by 5.76% to $360000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $360000.0, $382000.0, and $144000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | 2.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.02 Mn |
| Mar 31, 2026 | 360,000.00 |
| Dec 31, 2025 | 382,000.00 |
| Sep 30, 2025 | 144,000.00 |
| Jun 30, 2025 | 433,000.00 |
| Mar 31, 2025 | 397,000.00 |
| Dec 31, 2024 | 499,000.00 |
| Sep 30, 2024 | 452,000.00 |
| Jun 30, 2024 | 449,000.00 |
| Mar 31, 2024 | 379,000.00 |
| Dec 31, 2023 | 51,000.00 |
| Sep 30, 2023 | 51,000.00 |
| Jun 30, 2023 | 51,000.00 |
| Mar 31, 2023 | 39,000.00 |
| Dec 31, 2022 | 1.63 Mn |